Anadys/Novartis Hepatitis C Candidate Could Be Back In The Clinic By Year End

A 13-week preclinical toxicology study of ANA975 aims to explain dose dependence and immune stimulation concerns that led to FDA’s clinical hold for the toll-like receptor agonist.